keyword
https://read.qxmd.com/read/37440406/stat3-regulates-antiviral-immunity-by-suppressing-excessive-interferon-signaling
#1
JOURNAL ARTICLE
Shasha Liu, Siya Liu, Ziding Yu, Wenzhuo Zhou, Meichun Zheng, Rongrong Gu, Jinxuan Hong, Zhou Yang, Xiaojuan Chi, Guijie Guo, Xinxin Li, Na Chen, Shile Huang, Song Wang, Ji-Long Chen
This study identifies interleukin-6 (IL-6)-independent phosphorylation of STAT3 Y705 at the early stage of infection with several viruses, including influenza A virus (IAV). Such activation of STAT3 is dependent on the retinoic acid-induced gene I/mitochondrial antiviral-signaling protein/spleen tyrosine kinase (RIG-I/MAVS/Syk) axis and critical for antiviral immunity. We generate STAT3Y705F/+ knockin mice that display a remarkably suppressed antiviral response to IAV infection, as evidenced by impaired expression of several antiviral genes, severe lung tissue injury, and poor survival compared with wild-type animals...
July 11, 2023: Cell Reports
https://read.qxmd.com/read/31958364/jmjd6-stat3-y705ph-axis-promotes-autophagy-in-osteosarcoma-cancer-cells-by-regulating-atg
#2
JOURNAL ARTICLE
Kun Wang, Baoyin Du, Bin Xu, Xin Lv
BACKGROUND: Osteosarcoma cancer is a malignant tumor with poor outcome. Activation of STAT3 is closely related with tumor development. We intended to study the effects of JMJD6 on phosphorylation of STAT3 at Y705 site. METHODS: Osteosarcoma cancer cell lines (Saos-2, MG-63, and HOS) and clinical specimens were obtained. Interference RNA or JMJD6 mimic was transfected into the cells to silence or mimic JMJD6. Immunoprecipitation assay and glutathione S-transferase (GST) pull down was implemented to investigate whether JMJD6 is associated with STAT3...
January 20, 2020: BioFactors
https://read.qxmd.com/read/26208907/stat3-inhibition-enhances-the-therapeutic-efficacy-of-immunogenic-chemotherapy-by-stimulating-type-1-interferon-production-by-cancer-cells
#3
JOURNAL ARTICLE
Heng Yang, Takahiro Yamazaki, Federico Pietrocola, Heng Zhou, Laurence Zitvogel, Yuting Ma, Guido Kroemer
STAT3 is an oncogenic transcription factor with potent immunosuppressive functions. We found that pharmacologic inhibition of STAT3 or its selective knockout in cancer cells improved the tumor growth-inhibitory efficacy of anthracycline-based chemotherapies. This combined effect of STAT3 inhibition/depletion and anthracyclines was only found in tumors growing on immunocompetent (not in immunodeficient) mice. As compared with Stat3-sufficient control tumors, Stat3(-/-) cancer cells exhibited an increased infiltration by dendritic cells and cytotoxic T lymphocytes after chemotherapy...
September 15, 2015: Cancer Research
https://read.qxmd.com/read/22753933/targeting-stat3-induces-senescence-in-tumor-cells-and-elicits-prophylactic-and-therapeutic-immune-responses-against-breast-cancer-growth-mediated-by-nk-cells-and-cd4-t-cells
#4
JOURNAL ARTICLE
Mercedes Tkach, Lorena Coria, Cinthia Rosemblit, Martín A Rivas, Cecilia J Proietti, María Celeste Díaz Flaqué, Wendy Beguelin, Isabel Frahm, Eduardo H Charreau, Juliana Cassataro, Patricia V Elizalde, Roxana Schillaci
Aberrant Stat3 activation and signaling contribute to malignant transformation by promoting cell cycle progression, inhibiting apoptosis, and mediating tumor immune evasion. Stat3 inhibition in tumor cells induces the expression of chemokines and proinflammatory cytokines, so we proposed to apply Stat3-inhibited breast cancer cells as a source of immunogens to induce an antitumor immune response. Studies were performed in two murine breast cancer models in which Stat3 is activated: progestin-dependent C4HD cells and 4T1 cells...
August 1, 2012: Journal of Immunology
https://read.qxmd.com/read/19421230/stat3-transcription-factor-is-constitutively-activated-and-is-oncogenic-in-nasal-type-nk-t-cell-lymphoma
#5
JOURNAL ARTICLE
P Coppo, V Gouilleux-Gruart, Y Huang, H Bouhlal, H Bouamar, S Bouchet, C Perrot, V Vieillard, P Dartigues, P Gaulard, F Agbalika, L Douay, K Lassoued, N-C Gorin
Nasal-type natural killer (NK) cell lymphoma is an infrequent aggressive malignant disease with very poor prognosis. We aimed to explore the possible role of the transcription factor STAT3 in the pathophysiology of this malignancy, as it was involved in oncogenesis and chemoresistance. For this, we established and characterized a continuous interleukin 2-dependent NK cell line (MEC04) from a patient with a fatal nasal-type NK-cell lymphoma. Cells harbored poor cytotoxic activity against K562 cells, and spontaneously secreted interferon-gamma, interleukin-10 and vascular-endothelium growth factor in vitro...
September 2009: Leukemia
https://read.qxmd.com/read/15894558/il-6-induces-neuroendocrine-dedifferentiation-and-cell-proliferation-in-non-small-cell-lung-cancer-cells
#6
JOURNAL ARTICLE
Kuo-Ting Chang, Chun-Ming Tsai, Yih-Chy Chiou, Chao-Hua Chiu, King-Song Jeng, Chi-Ying F Huang
Interleukin-6 (IL-6) has been identified as an important growth regulator of lung cancer cells. Elevation of serum levels of IL-6 has been found in a subpopulation of lung cancer patients, but rarely in patients with benign lung diseases. Approximately 15% of non-small cell lung cancer (NSCLC) tumors exhibit neuroendocrine (NE) properties (NSCLC-NE) and have been suggested to have the biological characteristics similar to small cell lung cancer (SCLC) with early metastasis and initial responsiveness to chemotherapy...
September 2005: American Journal of Physiology. Lung Cellular and Molecular Physiology
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.